* known hypersensitivity to budesonide or to any of the excipients of the medicine; * hemostasis disorder, or epistaxis; * oromo-oral-nasal and ophthalmic herpes virus infection; * long-term corticosteroid treatment; * treatment with potent cyp3a4 inhibitors (e.g., cyp3a4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and hiv proteases) ; * forms of cov-2-sars with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms; * hyposmia persisting for more than 90 days after onset of symptoms; * other causes of hyposmia revealed on interrogation or an mri;

* known hypersensitivity to budesonide or to any of the excipients of the medicine; * hemostasis disorder, or epistaxis; * oromo-oral-nasal and ophthalmic herpes virus infection; * long-term corticosteroid treatment; * treatment with potent cyp3a4 inhibitors (e.g., cyp3a4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and hiv proteases) ; * forms of cov-2-sars with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms; * hyposmia persisting for more than 90 days after onset of symptoms; * other causes of hyposmia revealed on interrogation or an mri;

- known hypersensitivity to budesonide or to any of the excipients of the medicine; - hemostasis disorder, or epistaxis; - oromo-oral-nasal and ophthalmic herpes virus infection; - long-term corticosteroid treatment; - treatment with potent cyp3a4 inhibitors (e.g., cyp3a4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and hiv proteases) ; - forms of cov-2-sars with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms; - hyposmia persisting for more than 90 days after onset of symptoms; - other causes of hyposmia revealed on interrogation or an mri;

- known hypersensitivity to budesonide or to any of the excipients of the medicine; - hemostasis disorder, or epistaxis; - oromo-oral-nasal and ophthalmic herpes virus infection; - long-term corticosteroid treatment; - treatment with potent cyp3a4 inhibitors (e.g., cyp3a4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and hiv proteases) ; - forms of cov-2-sars with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms; - hyposmia persisting for more than 90 days after onset of symptoms; - other causes of hyposmia revealed on interrogation or an mri;